Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyOxaprotiline
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Oxaprotiline
- Accession Number
- DB09307
- Type
- Small Molecule
- Groups
- Experimental
- Description
Oxaprotiline is a norepinephrine reuptake inhibitor of the tetracyclic antidepressant family that is related to maprotiline. Though investigated as an antidepressant, it was never marketed. Oxaprotiline is a racemic compound composed of two isomers, R(−)- or levo- oxaprotiline (levoprotiline; CGP-12,103-A), and S(+)- or dextro- oxaprotiline (dextroprotiline; CGP-12,104-A). Both enantiomers are active, with the levo- form acting merely as an antihistamine and the dextro- form having a more expansive pharmacology, but with both unexpectedly still retaining antidepressant effects.
- Synonyms
- Hydroxymaprotiline
- Categories
- UNII
- 3V3Z2HK4LS
- CAS number
- 56433-44-4
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
Investigated for the treatment of depression.
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction (R)-warfarin The risk or severity of adverse effects can be increased when Oxaprotiline is combined with (R)-warfarin. (S)-Warfarin The risk or severity of adverse effects can be increased when Oxaprotiline is combined with (S)-Warfarin. 2,4-thiazolidinedione Oxaprotiline may decrease the hypoglycemic activities of 2,4-thiazolidinedione. 2,5-Dimethoxy-4-ethylamphetamine The risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Oxaprotiline. 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of serotonin syndrome can be increased when Oxaprotiline is combined with 2,5-Dimethoxy-4-ethylthioamphetamine. 3,4-Methylenedioxyamphetamine The risk or severity of serotonin syndrome can be increased when 3,4-Methylenedioxyamphetamine is combined with Oxaprotiline. 3,5-diiodothyropropionic acid The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when 3,5-diiodothyropropionic acid is combined with Oxaprotiline. 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of serotonin syndrome can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Oxaprotiline. 4-hydroxycoumarin The risk or severity of adverse effects can be increased when Oxaprotiline is combined with 4-hydroxycoumarin. 4-Methoxyamphetamine Oxaprotiline may increase the vasopressor activities of 4-Methoxyamphetamine. - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347910433
- Wikipedia
- Oxaprotiline
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Drug created on November 12, 2015 09:25 / Updated on November 02, 2018 07:01